title: Donor choice according to age for allo-SCT for AML in complete remission.
abstract: In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.
authors: Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ayuketan@uke.de
authors: F
authors: F
authors: Ayuk
authors: T
authors: T
authors: Zabelina
authors: F
authors: F
authors: Wortmann
authors: H
authors: H
authors: Alchalby
authors: C
authors: C
authors: Wolschke
authors: H
authors: H
authors: Lellek
authors: U
authors: U
authors: Bacher
authors: A
authors: A
authors: Zander
authors: N
authors: N
authors: Kröger
mesh_terms: D000328:Adult; D000367:Age Factors; D046148:Donor Selection / Q000379:methods* / Q000592:standards; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000592:standards; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000601:surgery*; D019520:Living Donors; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome